clinical trial · NCT05218655
A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
Inherited Mitochondrial DiseaseVatiquinone
brief summary
The primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical study or treatment plan. The study will continue until vatiquinone becomes commercially available or the program is terminated.
started
Jun 22, 2022
primary completion
Apr 15, 2025
completion
Apr 15, 2025
last updated
Dec 22, 2025
official title
An Open-Label, Safety Study for Previously Treated Vatiquinone (PTC743) Subjects With Inherited Mitochondrial Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol